<DOC>
<DOCNO>EP-0610134</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Indole derivatives as 5-HT1-like agonists
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D41314	A61P2500	C07D40314	C07D41306	C07D40300	C07D41914	A61K31415	A61K31415	C07D40306	C07D41300	A61K3140	A61K3140	A61P2504	C07D41900	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	A61P	C07D	C07D	C07D	C07D	A61K	A61K	C07D	C07D	A61K	A61K	A61P	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D413	A61P25	C07D403	C07D413	C07D403	C07D419	A61K31	A61K31	C07D403	C07D413	A61K31	A61K31	A61P25	C07D419	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to the compounds of formula (I): 
<
IMAGE
>
  in which:   R1 represents a hydrogen or halogen atom, an alkyl, alkoxy, cyano or aminocarbonyl group or any one of the following groups: 
<
IMAGE
>
  -(CH2)m-NH-COR6, -(CH2)m-NH-SO2-R4, 
<
IMAGE
>
  -(CH2)m-NH-CO-NHR4, 
<
IMAGE
>
  -(CH2)m-SO2-NH-R4, -CH=CH-SO2-NH-R4, 
<
IMAGE
>
  in which:     m is equal to 1, 2 or 3,   n is equal to 0, 1 or 2,   T represents a CO or SO2, R4 or R5, which are identical or different, represent a hydrogen atom or an alkyl or phenyl group,     R2 represents a hydrogen atom or an alkyl, phenyl or acyl group, R3 represents a hydrogen atom or an alkyl (optionally substituted by a hydroxyl or phenyl group) or alkoxycarbonyl group,   -X-Y= represents -N-C=, -N-N= or else 
<
IMAGE
>
  represents -O-N=, to their enantiomers, diastereoisomers and epimers and to their addition salts with a pharmaceutically acceptable acid. Medicaments.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of formula (I): 

 
wherein: 


R
1
represents a hydrogen or halogen atom, a linear or branched (C
1
-C
6
)alkyl, linear or 
branched (C
1
-C
6
) alkoxy, cyano or aminocarbonyl group, or any one of the 

 
following groups: 

wherein: 
m
is 1,2 or 3, 
n
is 0,1 or 2, 
T
represents a CO or SO
2
 group,  
 
R
4
and R
5
, which may be identical or different, represent a hydrogen atom, a 
linear or branched (C
1
-C
6
)alkyl or phenyl group (unsubstituted or substituted 
by one or more halogen atoms or trihalomethyl groups), 
R
2
represents a hydrogen atom, a linear or branched (C
1
-C
6
)alkyl or phenyl group 
(unsubstituted or substituted by one or more halogen atoms or trihalomethyl 

groups), 
R
3
represents a hydrogen atom, a linear or branched (C
1
-C
6
)alkyl group (optionally 
substituted by a hydroxy group or a phenyl group (itself unsubstituted or 

substituted by one or more halogen atoms or trihalomethyl groups)) or a linear or 
branched (C
1
-C
6
)alkoxycarbonyl group, 
 
enantiomers, diastereoisomers and epimers thereof and addition salts thereof with a 

pharmaceutically acceptable acid. 
Compounds of formula (1) according to claim 1, wherein R
2
 represents a hydrogen 
atom. 
Compounds of formula (I) according to claim 1, wherein R
1
 is located in the 
5-position of the phenyl nucleus. 
Compounds of formula (I) according to claim 1, wherein R
3
 represents a benzyl 
group. 
Compounds of formula (I) according to claim 1, wherein R
3
 represents a linear or 
branched (C
1
-C
6
)alkyl group. 
Compound of formula (I) according to claim 1 that is 3-[(1-propylpyrrolidin-3-yl)methyl]-5-aminocarbonylindole. 
Process for the preparation of compounds of formula (I) according to claim 1, 
characterised in that there is used as starting material an isatin of formula (II):  

 

 
wherein R'
1
 represents a hydrogen atom, a halogen atom, a linear or branched 
(C
1
-C
6
)alkyl group or a linear or branched (C
1
-C
6
)alkoxy group,
 
which is converted into the corresponding anion with sodium in the presence of sodium 

hydride, which is then condensed with the magnesium compound of formula (III): 

 
wherein R, R', R'', which may be identical or different, represent a halogen atom or an 

alkyl, alkoxy or trihalomethyl group,
 
to yield a compound of formula (IV): 


 
wherein R'
1
, R, R' and R'' are as defined hereinbefore,
 
which is subjected to the action of lithium aluminium hydride to yield a compound of 

formula 

 
(I/a): 

wherein R'
1
, R, R' and R'' are as defined hereinbefore,
  
 

the R'
1
 radical of which compound of formula (I/a), when that radical represents a 
bromine atom, is, if desired, converted into a cyano group and then into one of the 

other groups as defined for formula (I), according to conventional techniques of organic 
chemistry, and which compound is optionally subjected
 
   to the action of ethanolic HCl solution followed by debenzylation by hydrogenolysis 

to yield a compound of formula (I/b), a particular case of the compounds of 
formula (I): 


 
   wherein R
1
 is as defined for formula (I),
 
   and then, if desired, to the action of the halogen compound of formula (V): 


BrR'
3
, 
   wherein R'
3
 represents a linear or branched (C
1
-C
6
)alkyl group optionally 
substituted by a hydroxy group,
 
   to yield a compound of formula (I/c), a particular case of the compounds of 

formula (I): 

 
wherein R
1
 and R'
3
 are as defined hereinbefore,
  
 

   which compound of formula (I/a), (I/b) or (I/c) is subjected, where necessary, to 
the action of an iodinated benzene compound, which may be unsubstituted or 

substituted, in the presence of copper, or to the action of an alkyl halide or of an 
acyl halide,
 
   to yield a compound of formula (I/d), a particular case of the compounds of 

formula (I): 

 
   wherein R
1
 and R
3
 are as defined for formula (I) and R'
2
 represents a linear or 
branched (C
1
-C
6
)alkyl, phenyl (unsubstituted or substituted by one or more 
halogen atoms or alkyl, alkoxy or triha
lomethyl groups) or acyl group,
 
which compound of formula (I/a), (I/b), (I/c) or (I/d) 


is purified, if necessary, according to a conventional purification technique, 
is separated, if desired, into its isomers according to a conventional purification 
technique, 
is converted, where appropriate, into its addition salts with a pharmaceutically 
acceptable acid. 
Pharmaceutical compositions comprising as active ingredient at least one compound 
according to any one of claims 1 to 6, alone or in combination with one or more 

pharmaceutically acceptable, inert, non-toxic carriers. 
Pharmaceutical compositions according to claim 8 for use in the treatment of 
migraine and associated disorders. 
</CLAIMS>
</TEXT>
</DOC>
